TABLE 1.
Participant characteristics
| N = 50 | |
|---|---|
| Gender | |
| Male | 28 (56%) |
| Female | 22 (44%) |
| Race | |
| African-American | 7 (14%) |
| Caucasian | 43 (86%) |
| Diagnosis | |
| Brain tumor | 31 (62%) |
| Non-brain tumor | 19 (38%) |
| Age at diagnosis (yrs) | |
| Mean | 7.39 |
| Median (Range) | 6.90 (0.40 – 16.20) |
| Age at screening (yrs) | |
| Mean | 13.2 |
| Median (Range) | 14.2 (6.1 – 17.99) |
| Brain Surgery | |
| Yes | 31 (62%) |
| No | 19 (38%) |
| Primary tumor in brain | |
| None/biopsy of brain | 5 (10%) |
| Partial/total resection | 27 (54%) |
| No primary tumor in brain | |
| None/biopsy of brain | 18 (36%) |
| Radiation to head/neck | |
| Yes | 35 (70%) |
| No | 15 (30%) |
| Cisplatin | |
| Yes | 19 (38%) |
| No | 31 (62%) |
| Carboplatin | |
| Yes | 14 (28%) |
| No | 36 (72%) |
| Vancomycin | |
| Yes | 9 (19.6%) |
| No | 37 (80.4%) |
| Missing | 4 |
| Aminoglycosides | |
| Yes | 3 (6.5%) |
| No | 43 (93.5%) |
| Missing | 4 |
| Hearing loss | |
| Yes | 17 (40.5%) |
| No | 25 (59.5%) |
| Missing | 8 |
| End of treatment to screening (yrs) | |
| Mean | 4.77 |
| Median (Range) | 4.25 (0.17 – 13.88) |